Systemic Features and Prognosis of BPES
BPES is a rare congenital disorder characterized by four cardinal ocular features (blepharophimosis, ptosis, epicanthus inversus, and telecanthus), with Type I additionally causing premature ovarian insufficiency (POI) in females, while Type II presents with isolated eyelid abnormalities and normal fertility.
Classification and Genetic Basis
BPES is caused by mutations in the FOXL2 gene located at chromosome 3q23, with genetic defects identifiable in approximately 88% of clinically diagnosed cases 1. The syndrome divides into two distinct types:
- Type I BPES: Eyelid malformations plus POI in females
- Type II BPES: Isolated eyelid abnormalities without ovarian involvement
The type of genetic mutation strongly predicts prognosis—truncation variants are significantly more likely to cause Type I BPES (73.8% of cases) compared to Type II (19.6%), making genetic testing valuable for predicting ovarian involvement 2.
Ocular Features and Outcomes
The four cardinal ocular features present at birth include:
- Short horizontal palpebral fissures (blepharophimosis)
- Drooping eyelids (ptosis)
- Vertical skin fold from lower eyelid extending along the nose (epicanthus inversus)
- Lateral displacement of inner canthi with normal interpupillary distance (telecanthus)
Visual complications are common and include amblyopia and astigmatism, requiring early surgical intervention to prevent permanent vision loss 3. Surgical correction typically proceeds in two stages: first addressing epicanthus inversus and telecanthus (around age 3-4 years), followed by ptosis correction 9-12 months later 4. Early surgery may be necessary if amblyopia develops 4.
Systemic Features Beyond the Eyes
Female Reproductive System (Type I Only)
Premature ovarian insufficiency is the most significant systemic complication in Type I BPES, requiring lifelong hormone replacement therapy and fertility counseling 5. POI in BPES presents as:
- Loss of ovarian activity before age 40
- Menstrual disturbances (amenorrhea or oligomenorrhea)
- Elevated gonadotropins with low estradiol 6
According to ESHRE guidelines, autosomal genetic testing for FOXL2 is specifically indicated when BPES is suspected, unlike most other POI cases where genetic testing is not routinely recommended 6.
Additional Systemic Associations
While patients with classic BPES typically have normal lifespans 7, larger deletions encompassing FOXL2 can present with:
- Developmental delay or intellectual disability 7
- Spastic diplegia 7
- Speech delay 7
- Genital anomalies in males 7
- Rarely: cleft palate and cardiomyopathy 8
These additional features occur more frequently when BPES results from larger chromosomal deletions rather than isolated FOXL2 mutations 7.
Prognosis and Management Implications
For Females with Type I BPES:
Hormone replacement therapy should be initiated promptly upon diagnosis of POI to prevent long-term complications including osteoporosis and cardiovascular disease 5. The fertility prognosis is generally poor, particularly with DNA repair gene involvement 1.
Every female patient diagnosed with POI should be specifically examined for BPES ocular features, as early diagnosis allows for appropriate genetic counseling and family planning 5.
For All BPES Patients:
- Visual prognosis depends on timely surgical intervention before amblyopia becomes irreversible
- Genetic counseling is essential given autosomal dominant inheritance pattern
- Family screening should be performed when FOXL2 mutations are identified 1
Genetic Testing Strategy:
Molecular testing for FOXL2 should be performed after obtaining informed consent, as identifying truncation variants helps predict Type I versus Type II disease and guides reproductive counseling 1, 2. Approximately 81% of genetic defects are intragenic FOXL2 mutations, 10-12% are microdeletions, and 5% involve regulatory region deletions 7.
Critical Clinical Pitfalls
Do not assume BPES is Type II (isolated ocular) in young female patients—ovarian function testing should be performed even before puberty to enable early intervention planning 9. The functional studies showing abnormal transcriptional activity on steroidogenic genes (StAR/STARD1) provide mechanistic insight into why early endocrine follow-up is crucial 9.
Patients with BPES-like features but incomplete phenotype may have other copy number variations detected in 33% of cases, warranting comprehensive genetic evaluation beyond FOXL2 alone 7, 10.